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Des-aspartate angiotensin I (DAA-I) is a short-acting
peptide molecule comprising nine amino acids, whose
main role is to block angiotensin II via agonistic activity on
the angiotensin AT1 receptor [1]. Lee et al. recently
reported the safety, tolerability and pharmacokinetics of
DAA-1 in healthy subjects who received single escalating
doses of DAA-1 in an extemporaneously prepared oral
formulation [2]. This study in particular assumes impor-
tance primarily because hitherto no such human clinical
pharmacology data pertaining to DAA-1 have been pub-
lished [2].
The safety and tolerability data gathered in this study
showed no inadvertent effects and/or adverse events asso-
ciated with DAA-1. However, the lack of differentiation in
the single-dose pharmacokinetics of the examined three
active doses in relation to placebo [2] poses a challenge in
developing a cohesive clinical development plan for the
advancement of DAA-1. Because of the rapid degradation
of DAA-1, it was not expected that the first exogenous dose
of DAA-1 at 0.08 mg/kg would show appreciable plasma
levels in the human subjects [2]. Interestingly, the other
two higher doses of DAA-1 (i.e., 0.7 and 1.5 mg/kg)
appeared to be equally rapidly metabolized, resulting in no
appreciable systemic levels of DAA-1 [2]. Perhaps one
limitation of the study, as pointed out by the authors, was
related to the frequency of pharmacokinetic sample time
collection; perhaps, the inclusion of early time points after
oral administration in a 2- to 3-min interval for the first 30
min after dosing may have provided a better opportunity to
pick the transient elevated levels of DAA-1 in the systemic
circulation.
On one hand, the development of exogenous DAA-1 is
an exciting prospect from a clinical perspective, given the
wide range of therapeutic interventions it could be applied
to [3–5]. On the other hand, it represents an insurmount-
able challenge to develop DAA-1 from a clinical devel-
opment perspective. The intent of this note is to provide
some thoughts on developing DAA-1 as a potential drug
candidate.
Peptide drug delivery via the oral route is a daunting
task owing to instability of peptides in the local environ-
ment of the gastrointestinal tract [6, 7]. Therefore, the lack
of any DAA-1 levels above and beyond the baseline levels
in the systemic circulation observed in this study is testa-
ment to the extent of the problem that needs to be over-
come. The occasional spikes in the mean systemic levels of
DAA-1, especially observed in later time points, were
merely a reflection of the variability of the endogenously
occurring DAA-1, rather than absorption from the admin-
istered DAA-1 doses [2]. In addition, none of the observed
parameters such as vital signs, aldosterone levels, liver
function biomarkers and renal function biomarkers showed
any differences to discern a clear DAA-1 effect versus
placebo effect. Overall, the single-dose data for DAA-1,
although suggestive of an excellent safety/tolerability
profile, have failed to provide any clues that would aid the
developmental aspects of DAA-1.
The key question is how would one design a multiple-
dose escalation study of DAA-1 in humans to obtain
meaningful data. What would be the starting dose and the
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frequency of multiple-dosing regimens? What would be the
cap, if any, on the highest dose of DAA-1 to be adminis-
tered in the study? These questions are rather difficult to
answer, especially if the orally administered DAA-1 is
rapidly metabolized and/or de-stabilized in the gastroin-
testinal tract.
Therefore, as a drug developer it may become important
to find innovative ways to tackle such tricky issues. Prior to
investment of resources for the whole clinical development
program, it may be vital to ascertain the proof of concept of
the desired effect of DAA-1. Although the authors’ sug-
gestion of using circulatory prostaglandin entities such as
prostaglandin E2 (PGE2) or prostaglandin I2 (PGI2) as
target biomarkers may be potentially considered [2], it
would still fall short of the much desired confirmatory
pharmacological activity of DAA-1 for allocation of
resources for full-scale drug development. Hence, to better
understand the pharmacodynamics of exogenous DAA-1
and obtain proof of concept of its pharmacological activity,
one might consider DAA-1 given in a combination regimen
with another agent, using an established surrogate marker
such as blood pressure.
In order to establish the proof of concept of DAA-1, two
other companion classes of drugs, namely, angiotensin-
converting-enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs), may be potentially considered.
The design may involve the addition of DAA-1 to either an
ACEI- or ARB-stabilized regimen that may help in the
reduction of the stable doses of either ACEI or ARB
companion drug in the relevant patient population. Per-
haps, the highest dose of DAA-1 tested in the single-dose
escalating study (i.e., 1.5 mg/kg) could potentially be
added to the stable dose regimen of either ACEI or ARB in
a twice daily (bid) dosing regimen of DAA-1 with con-
comitant reduction in the respective dose of either the
ACEI or ARB. Alternatively another design may be to
randomize a group of patients on stable doses of either
ACEI or ARB to two experimental groups: one group
would continue to be on the stable dose of either of the two
drugs, while the other group would receive approximately
50% of the stable dose of either of the two drugs along with
the highest tested dose of DAA-1 (bid regimen). Regard-
less of the design adopted, after a specific time period, the
measurement of blood pressure as the surrogate would
establish the proof of concept of DAA-1.
Overall, development of peptide drugs via the oral route
represents a considerable challenge as manifested for other
drugs, most notably insulin [8]. Hence, as a first step it may
be crucial to understand the proof of concept whether such
a route (i.e., oral) is amenable for DAA-1 and what may be
the minimal dose requirement/regimen to achieve the proof
of concept.
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